Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse

AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant Mice

(2011) Yu Li et al.   Cell Metabolism

Therapeutic effects of ezetimibe for non-alcoholic steatohepatitis in fatty liver shionogi-ob/ob mice

(2011) Tomomitsu Matono et al.   HEPATOLOGY RESEARCH

Romo1 is a negative-feedback regulator of Myc

(2011) S. B. Lee et al.   JOURNAL OF CELL SCIENCE

Novel Findings for the Development of Drug Therapy for Various Liver Diseases: Liver Microsomal Triglyceride Transfer Protein Activator May Be a Possible Therapeutic Agent in Non-alcoholic Steatohepatitis

(2011) Koji Fujita et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease

(2011) Isabel VA Pereira et al.   Expert Review of Gastroenterology & Hepatology

Induction of microsomal triglyceride transfer protein expression is a candidate mechanism by which ezetimibe therapy might exert beneficial effects in patients with nonalcoholic steatohepatitis

(2010) Masato Yoneda et al.   JOURNAL OF GASTROENTEROLOGY

Involvement of microsomal triglyceride transfer protein in nonalcoholic steatohepatitis in novel spontaneous mouse model

(2010) Nobuyasu Shindo et al.   JOURNAL OF HEPATOLOGY

Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet

(2010) Tomonori Muraoka et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance

(2009) Mitsunori Nomura et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

A Novel Mouse Model for Type 2 Diabetes and Non-alcoholic Fatty Liver Disease: Spontaneous Amelioration of Diabetes by Augmented Beta Cell Mass

(2009) Aya OZE-FUKAI et al.   ENDOCRINE JOURNAL

Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis

(2009) Koji Fujita et al.   HEPATOLOGY

Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease

(2009) Yuichi Nozaki et al.   JOURNAL OF HEPATOLOGY

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

(2008) Shuqin Zheng et al.   EUROPEAN JOURNAL OF PHARMACOLOGY